W. Daniel Kissling

W. Daniel Kissling's AcademicInfluence.com Rankings

W. Daniel Kissling

Biology

#12340

World Rank

#15811

Historical Rank

Ecology

#747

World Rank

#812

Historical Rank

biology Degrees

Download Badge

Biology

W. Daniel Kissling's Degrees

PhD Ecology University of Copenhagen
Masters Biology University of Copenhagen

Similar Degrees You Can Earn

Best Online Master's in Biology

Why Is W. Daniel Kissling Influential?

(Suggest an Edit or Addition)

(See a Problem?)

W. Daniel Kissling's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis (2013) (1929)
What does the PANSS mean? (2005) (991)
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials (1999) (795)
Clinical implications of Brief Psychiatric Rating Scale scores. (2005) (710)
Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis (2012) (702)
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis (2010) (612)
The effect of family interventions on relapse and rehospitalization in schizophrenia--a meta-analysis. (2015) (596)
New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis (2003) (524)
Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. (2003) (456)
How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials (2009) (439)
Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. (2006) (406)
Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses (2012) (343)
Guidelines for depot antipsychotic treatment in schizophrenia (1998) (312)
Oral versus depot antipsychotic drugs for schizophrenia—A critical systematic review and meta-analysis of randomised long-term trials (2011) (299)
How to understand species’ niches and range dynamics: a demographic research agenda for biogeography (2012) (277)
Shared decision making for in‐patients with schizophrenia (2006) (273)
Linking the PANSS, BPRS, and CGI: Clinical Implications (2006) (267)
Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. (2002) (265)
Maintenance treatment with antipsychotic drugs for schizophrenia. (2012) (252)
Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. (2010) (244)
Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses. (2014) (239)
Do patients with schizophrenia wish to be involved in decisions about their medical treatment? (2005) (234)
Early-Onset Hypothesis of Antipsychotic Drug Action: A Hypothesis Tested, Confirmed and Extended (2005) (208)
Olanzapine versus other atypical antipsychotics for schizophrenia. (2010) (204)
Definitions of response and remission in schizophrenia: recommendations for their use and their presentation (2009) (190)
Shared decision making in psychiatry (2003) (173)
Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. (2005) (171)
Shared decision making and long-term outcome in schizophrenia treatment. (2007) (167)
Second-generation antipsychotics for major depressive disorder and dysthymia. (2010) (166)
Second-generation antipsychotics for schizophrenia: can we resolve the conflict? (2009) (158)
Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. (2004) (155)
Attitudes of psychiatrists toward antipsychotic depot medication. (2006) (150)
Psychoeducation and compliance in the treatment of schizophrenia: results of the Munich Psychosis Information Project Study. (2006) (149)
Psychiatrists' use of shared decision making in the treatment of schizophrenia: patient characteristics and decision topics. (2009) (148)
beta-Endorphin-like immunoreactivity in cerebrospinal fluid and plasma of patients with schizophrenia and other neuropsychiatric disorders. (1979) (145)
Participation preferences of patients with acute and chronic conditions (2007) (142)
Extending point pattern analysis for objects of finite size and irregular shape (2006) (131)
Psychoeducation in schizophrenia--results of a survey of all psychiatric institutions in Germany, Austria, and Switzerland. (2005) (127)
Early prediction of antipsychotic nonresponse among patients with schizophrenia. (2007) (121)
Guidelines for Neuroleptic Relapse Prevention in Schizophrenia (1991) (116)
Risperidone versus other atypical antipsychotics for schizophrenia. (2011) (110)
Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. (1998) (106)
Quetiapine versus other atypical antipsychotics for schizophrenia. (2010) (103)
Antidepressants for the negative symptoms of schizophrenia. (2006) (98)
Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. (2001) (90)
Psychoeducation in schizophrenia: new developments and approaches in the field (2008) (88)
Compliance, quality assurance and standards for relapse prevention in schizophrenia (1994) (87)
Second-generation antipsychotics for obsessive compulsive disorder. (2010) (86)
Trends and perspectives of shared decision-making in schizophrenia and related disorders (2014) (85)
Future climate change driven sea‐level rise: secondary consequences from human displacement for island biodiversity (2012) (85)
Second-generation antipsychotics for anxiety disorders. (2010) (82)
Ziprasidone versus other atypical antipsychotics for schizophrenia. (2009) (82)
Effect of sodium valproate on mania (2004) (82)
Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: A systematic review of randomized trials (2005) (77)
Local forest structure, climate and human disturbance determine regional distribution of boreal bird species richness in Alberta, Canada (2013) (76)
Confirmation bias: why psychiatrists stick to wrong preliminary diagnoses (2011) (69)
A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. (2002) (69)
Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials. (2004) (67)
The PANSS should be rescaled. (2010) (66)
Medical decision making in antipsychotic drug choice for schizophrenia. (2004) (66)
"How to speak to your psychiatrist": shared decision-making training for inpatients with schizophrenia. (2011) (66)
Evidence-based pharmacotherapy of schizophrenia. (2011) (65)
Patients’ and Psychiatrists’ Perceptions of Clinical Decisions During Schizophrenia Treatment (2008) (64)
Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials (2004) (64)
Compliance, quality assurance and standards for relapse prevention in schizophrenia. (1994) (63)
New generation antipsychotics for first episode schizophrenia. (2003) (60)
ANTIDEPRESSANT EFFECTS OF BUPRENORPHINE (1982) (59)
Carbamazepine for schizophrenia. (2014) (59)
Direct transition to long-acting risperidone - analysis of long-term efficacy (2005) (58)
How to read and understand and use systematic reviews and meta‐analyses (2009) (58)
Partial Compliance With Antipsychotic Medication is Common in Patients With Schizophrenia (2008) (57)
Why do some patients with schizophrenia want to be engaged in medical decision making and others do not? (2011) (57)
Psychiatrists’ attitude to antipsychotic depot treatment in patients with first-episode schizophrenia (2011) (54)
Do physicians’ recommendations pull patients away from their preferred treatment options? (2012) (53)
Predicting antipsychotic drug response – Replication and extension to six weeks in an international olanzapine study (2008) (52)
Therapeutic effect of valproate in mania. (1981) (51)
On the concept of remission in schizophrenia (2007) (51)
Psychoeducation for patients with schizophrenia and their families (2008) (50)
How should patients behave to facilitate shared decision making – the doctors’ view (2012) (49)
Ideal and Reality of Neuroleptic Relapse Prevention (1992) (49)
Carbamazepine augmentation for schizophrenia: how good is the evidence? (2002) (46)
Amisulpride is an “atypical” antipsychotic associated with low weight gain (2004) (46)
Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. (2014) (45)
Towards a comprehensive climate impacts assessment of solar geoengineering (2017) (45)
Amisulpride versus other atypical antipsychotics for schizophrenia. (2010) (45)
Doubleblind evaluation of the antimanic properties of carbamazepine as a comedication to haloperidol (1989) (44)
Double-blind multicenter study of paroxetine and amitriptyline in depressed inpatients. (1993) (43)
The current unsatisfactory state of relapse prevention in schizophrenic psychoses--suggestions for improvement. (1991) (42)
Peer-to-peer psychoeducation in schizophrenia: a new approach. (2005) (42)
Guidelines for Neuroleptic Relapse Prevention in Schizophrenia: Towards a Consensus View (1991) (41)
Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study. (1991) (41)
Comparative remission rates of schizophrenic patients using various remission criteria (2008) (38)
Improving outpatient treatment in schizophrenia: effects of computerized guideline implementation—results of a multicenter-study within the German Research Network on Schizophrenia (2010) (38)
Aripiprazole versus other atypical antipsychotics for schizophrenia. (2009) (37)
Action of propranolol in mania: comparison of effects of the d- and the l-stereoisomer. (1979) (37)
Identifying the profile of optimal candidates for antipsychotic depot therapy A cluster analysis (2008) (37)
Antipsychotic prescribing patterns in Germany: a retrospective analysis using a large outpatient prescription database (2003) (35)
Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months. (2008) (34)
Patient participation in antipsychotic drug choice decisions (2010) (34)
Carbamazepine for schizophrenia and schizoaffective psychoses. (2002) (34)
Lithium for schizophrenia. (2015) (34)
How do patients from eastern and western Germany compare with regard to their preferences for shared decision making? (2012) (33)
Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention. (1985) (33)
Managers' reactions towards employees' disclosure of psychiatric or somatic diagnoses (2013) (30)
How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed? (2010) (30)
Psychoeducation Improves Compliance and Outcome in Schizophrenia Without an Increase of Adverse Side Effects: A 7-Year Follow-up of the Munich PIP-Study. (2016) (29)
Effects of a question prompt sheet on active patient behaviour: A randomized controlled trial with depressed outpatients (2014) (28)
Des-Tyrosyl-γ-Endorphin in Schizophrenia (1980) (28)
'What would you do if you were me, doctor?': randomised trial of psychiatrists' personal v. professional perspectives on treatment recommendations. (2010) (28)
Frequency and relevance of psychoeducation in psychiatric diagnoses: Results of two surveys five years apart in German-speaking European countries (2013) (28)
Efficacy and side effects of haloperidol in psychotic patients: oral versus intravenous administration. (1982) (28)
Lithium for schizophrenia. (2007) (27)
On a possible role of GABA in mania. Therapeutic efficacy of sodium valproate. (1981) (26)
Can Psychiatrists and Neurologists Predict Their Patients' Participation Preferences? (2010) (25)
Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms (2007) (25)
Doxepin Plasma Concentrations: Is There Really a Therapeutic Range? (2001) (25)
Training patients with schizophrenia to share decisions with their psychiatrists: a randomized-controlled trial (2017) (24)
Using films as a psychoeducation tool for patients with schizophrenia: a pilot study using a quasi-experimental pre-post design (2015) (24)
Equipercentile linking of the Brief Psychiatric Rating Scale and the Clinical Global Impression Scale in a catchment area (2012) (24)
Checking the plausibility of psychiatrists׳ arguments for not prescribing depot medication (2014) (22)
Schizophrenic patients treated with high dose phenothiazine or thioxanthene become deficient in polyunsaturated fatty acids in their thrombocytes. (1992) (22)
Long‐term safety and efficacy of long‐acting risperidone in elderly psychotic patients (2007) (22)
Carbamazepine for schizophrenia. (2007) (22)
Sertindole versus other atypical antipsychotics for schizophrenia. (2009) (21)
Psychoeducation in anxiety disorders: Results of a survey of all psychiatric institutions in Germany, Austria and Switzerland (2009) (20)
European psychiatric treatment guidelines: is the glass half full or half empty? (2005) (20)
How do psychiatrists choose among different antipsychotics? (2005) (20)
Long-term observation of patients successfully switched to risperidone long-acting injectable: A retrospective, naturalistic 18-month mirror-image study of hospitalization rates and therapy costs (2010) (19)
DES-TYR1-γ-ENDORPHIN IN SCHIZOPHRENIA (1980) (19)
A “Mental-Health-at-the-Workplace” Educational Workshop Reduces Managers' Stigma Toward Depression (2016) (19)
Peer-counseling in schizophrenia: patients consult patients. (2008) (19)
Gender differences in patient and caregiver psychoeducation for schizophrenia (2010) (18)
Are the second-generation antipsychotics cost-effective? A critical review on the background of different health systems. (2003) (18)
Physicians' and patients' involvement in relapse prevention with antipsychotics in schizophrenia. (2005) (18)
[Prognostic value of the early response of psychiatric patients to neuroleptics for the subsequent course of treatment]. (1983) (18)
Numerical Simulation of CO 2 Sequestration in Natural CO 2 Reservoirs on the Colorado Plateau (2001) (17)
Zotepine versus other atypical antipsychotics for schizophrenia. (2010) (17)
Pharmacological Treatment of Schizophrenia (2013) (17)
Non‐response to antidepressants: risk factors and therapeutic possibilities (1988) (17)
A fast, implementable psychoeducation program for schizophrenia. (2007) (17)
A controlled study of the efficacy and safety of mianserin and amitriptyline in depressive inpatients. (1995) (16)
Psychiatrists' decision making between branded and generic drugs (2013) (16)
Psychiatric decision making in the adoption of a new antipsychotic in Germany. (2006) (16)
[Direct and indirect costs of schizophrenia]. (1999) (14)
Quality management in psychiatry. (2001) (14)
[Psychiatric patients and relatives instruct German police officers - an anti-stigma project of "BASTA - the alliance for mentally ill people"]. (2007) (14)
Polyunsaturated fatty acids in peroxisomal disorders: a hypothesis and a proposal for treatment. (1993) (14)
Serial application of clonidine tests during antidepressive treatment with chlorimipramine. (1984) (14)
Antipsychotic prescribing patterns in Germany: a retrospective analysis using a large outpatient prescription database. (2003) (14)
Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia (2012) (14)
Maintenance treatment with antipsychotic drugs for schizophrenia. (2020) (14)
Results of treatment of schizophrenia: is the glass half full or half empty? (1999) (13)
[Information-centered family groups for improving compliance in schizophrenic patients]. (1991) (13)
Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland (2008) (13)
Psychiatrist and patient responses to suspected medication nonadherence in schizophrenia spectrum disorders. (2014) (13)
Hemodialysis in schizophrenia: three failures with chronic patients. (1979) (12)
Double-Blind Comparison of Intravenous Versus Oral Maprotiline*. Antidepressant Activity, Plasma Levels, Side-Effects (1985) (12)
Action of [Des-Tyr1]-γ-Endorphin in Schizophrenia (1981) (12)
Language bias in neuroscience—is the Tower of Babel located in Germany? (2004) (12)
Treatment of schizophrenic disorders: Algorithms for acute pharmacotherapy. (1997) (11)
[Effects of a shared decision making model in psychiatric and neurologic practice]. (2006) (11)
Studies on a Possible Pathological Significance of Endorphins in Psychiatric Disorders (1979) (11)
Measurement of β-Endorphin-Like Immunoreactivity in CSF and Plasma of Neuropsychiatric Patients (1979) (10)
Plasma levels of beta-endorphin under chronic neuroleptic treatment in schizophrenic patients: failure of naloxone to counteract curative effects of neuroleptic drugs. (1980) (10)
Compliance, quality management and standards in the treatment of schizophrenia. (1997) (10)
The Character and Purpose of the Hebridean Black House (1943) (10)
Effects of an integrated care program for outpatients with affective or psychotic disorders (2014) (9)
Das Burnout-Syndrom: Prävalenz, Symptome, Differenzialdiagnose und Therapie (2014) (9)
[Patient participation in german psychiatry - a critical review]. (2008) (9)
Optimising Prophylactic Treatment of Schizophrenia by Means of Treatment Standards and Compliance Improvement (1992) (8)
Patients' acceptance of the deltoid application of risperidone long-acting injection (2012) (8)
Measurement of beta-endorphin-like immunoreactivity in CSF and plasma of neuropsychiatric patients. (1979) (8)
Are patients with schizophrenia under-treated with second-generation antipsychotics? A pilot study of the prescription practices of German psychiatrists. (2003) (8)
Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia (2007) (8)
Des-tyrosyl-gamma-endorphin in schizophrenia: a double-blind trial in 13 patients. (1980) (8)
Controlled trial on the possible advantages of a combined therapy with maprotiline and haloperidol in endogenous depression. (1986) (7)
Zotepine versus other atypical antipsychotics for schizophrenia. (2010) (7)
Call for a European Guidelines Institute (2006) (7)
Does it matter whether physicians' recommendations are given early or late in the decision-making process? An experimental study among patients with schizophrenia (2016) (7)
Duration of Neuroleptic Maintenance Treatment (1991) (7)
How psychiatrists inform themselves and their patients about risks and benefits of antipsychotic treatment (2009) (7)
medication into perspective: review of meta-analyses Putting the efficacy of psychiatric and general medicine (2012) (6)
The dexamethasone suppression test in depressive and schizophrenic patients under controlled treatment conditions (2004) (6)
Steigerung des „empowerment“ bei Angehörigen von schizophren Erkrankten (2012) (6)
Efficacy and tolerability of a new antipsychotic compound (savoxepine): results of a pilot-study. (1989) (6)
114. House Traditions in the Outer Hebrides. The Black House and the Beehive Hut (1944) (5)
Lithium for schizophrenia (Review) (2009) (5)
Kindstötung und hebephrenes Syndrom bei metachromatischer Leukodystrophie (1999) (5)
[Patient satisfaction with psychiatric care. Historical perspective, methods and results from the international literature]. (1999) (5)
Iconography : Psychiatrists’ attitude to antipsychotic depot treatment in patients with first-episode schizophrenia (2011) (5)
Caregiver psychoeducation for schizophrenia: Is gender important? – Comments on the study by McWilliams et al., 2007 (2007) (5)
[Understanding the term burnout in psychiatry and psychotherapy]. (2013) (4)
["Family members inform family members" - family members as group moderators for psychoeducational groups in schizophrenia]. (2005) (4)
CLINICAL TRIAL OF DES‐TYROSYL‐γ‐ENDORPHIN IN MENTAL ILLNESS (1982) (4)
A Fast, Implementable Psychoeducation Program for Schizophrenia (2007) (4)
Lithium for schizophrenia. (2003) (4)
Action of d-propranolol in manic psychoses (1979) (4)
Psychoeducation in dementia: Results of a survey of all psychiatric institutions in Germany, Austria and Switzerland (2008) (4)
Who is interested in the quality of everyday psychiatric care? (2001) (3)
CERP – CENTRES OF EXCELLENCE IN RELAPSE PREVENTION. AN INTERNATIONAL EDUCATIONAL PROGRAMME TO ENHANCE RELAPSE PREVENTION IN SCHIZOPHRENIA (2010) (3)
Is interpersonal fairness in the doctor-patient relationship associated with long-term compliance in patients with schizophrenia? (2013) (3)
Are new drugs for schizophrenia better than old ones? – Authors' reply (2009) (3)
Complaint-management in psychiatry – a nationwide survey in Germany (2007) (3)
Meta-analysis of amisulpride — A selective dopamine receptor antagonist with an “atypical” profile (2000) (3)
Advantages and disadvantages of depot-neuroleptics as maintenance medication for chronic schizophrenics. (1986) (3)
Guidelines for neuroleptic relapse prevention in schizophrenia : proceedings of a consensus conference held April 19-20, 1989, in Bruges, Belgium (1991) (3)
Hemodialysis in schizophrenia. Results in three chronic cases. (1979) (3)
Lithium for schizophrenia: A systematic review and meta-analysis (2000) (2)
Pretrial medication bias in randomized antipsychotic drug trials. (2007) (2)
Second‐generation antipsychotic drugs for major depressive disorder (2009) (2)
Second-generation antipsychotic drugs for obsessive compulsive disorder (2009) (2)
[Therapeutic decisions based on meta analyses]. (2008) (2)
PHARMACOGENETICS: GENOTYPING OF CYTOCHROMES P450 2D6 AND 2C19 IN PSYCHIATRIC PATIENTS TREATED WITH TRICYCLIC ANTIDEPRESSANTS (TCA) OR NEUROLEPTICS. (1999) (2)
Language Bias in Neuroscience – Is the Tower of Babel located in Germany? (2004) (2)
New generation versus conventional antipsychotics (2003) (2)
Drowning in Numbers–what Psychiatrists Mean when Talking to Patients about Probabilities of Risks and Benefits of Medication (2010) (2)
P.2.047 Shared decision making on antipsychotic drug choice for inpatients with schizophrenia (2004) (2)
Kompendium der Schizophreniebehandlung (1992) (2)
Different antipsychotics produce similar, small improvements in psychosocial functioning at one year in people with schizophrenia (2007) (2)
Can quality management improve the treatment of schizophrenic outpatients? (2000) (1)
[Prevention of relapse in schizophrenia is discontinued too soon. Many colleagues make this mistake!]. (2000) (1)
60. House Traditions in the Hebrides (1944) (1)
Efficacy and safety of SND 919, a new dopamine autoreceptor agonist in schizophrenia (1991) (1)
An update of meta-analyses on second-generation antipsychotic drugs for schizophrenia (2009) (1)
Depot-Neuroleptics in Acute Psychiatry (1985) (1)
Rapid Detection Of The Intermediate Metabolizer Associated CYP2D6 Polymorphisms *9 And *17 With Real Time PCR: 124 (2005) (1)
Second‐generation antipsychotic drugs for anxiety disorders (2009) (1)
How long do psychiatrists wait for response before they switch to another antipsychotic? (2007) (1)
Pretreated patients with up to 5-year history of psychosis show improved clinical outcome following therapy change to risperidone long-acting injectable (2004) (1)
[The police - there to serve and protect]. (2006) (1)
The Dopamine D4 Receptor 48 Base Pair Repeat Polymorphism Influences Antipsychotic Induced Body Weight Gain. A Preliminary Report: 123 (2005) (1)
[Homicide and hebephrenia-like syndrome in metachromatic leukodystrophy]. (1999) (1)
Early prediction of non-response - when should antipsychotic drugs be switched? (2007) (1)
[Psychoeducation in Depression: Results of two Surveys five Years Apart in Germany, Austria and Switzerland]. (2015) (1)
Clinical implications of Brief Psychiatric Rating Clinical implications of Brief Psychiatric Rating (2005) (1)
Neuroscience and the future of psychiatry (1999) (1)
Selective dopamine receptor antagonists with an ‘atypical’ profile? (2000) (1)
Enhancing empowerment for relatives of patients with schizophrenia. Results of a psychoeducational group program under naturalistic conditions (2012) (1)
Hemodialysis in schizophrenia (1979) (1)
[Mental health at the workplace - the view of companies]. (2013) (1)
Medication adherence studies in schizophrenia. (2004) (1)
[The "neuroleptic threshold"--a review of the literature]. (1996) (1)
P.3.030 Cochrane meta-analysis: antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms (2005) (1)
Hot and Saline Spring Behaviour in the Taupo Volcanic Zone and the North-East German Basin (2012) (1)
Essential Evidence-Based Psychopharmacology: Evidence-based pharmacotherapy of schizophrenia (2012) (1)
Federal Republic of Germany: Neuroleptic Relapse Prevention (1991) (1)
DOXEPIN SERUM CONCENTRATIONS: IS THERE REALLY A THERAPEUTIC RANGE? (1999) (1)
S-10-5 Advantages of atypical antipsychotics in the maintenance treatment of schizophrenia (1995) (0)
[Hemodialysis in patients with chronic schizophrenia (author's transl)]. (1980) (0)
Antipsychotic Agents (Neuroleptics): Efficacy and side effects of haloperidol in psychotic patients (1983) (0)
FIRST EVALUATION OF A NEW INFORMATION MANUAL TO IMPROVE COMPLIANCE AMONG SCHIZOPHRENIC PATIENTS (1992) (0)
Shared Decision Making in Schizophrenia Treatment. Authors' reply (2008) (0)
WHY IS A CONSENSUS ON GUIDELINES FOR NEUROLEPTIC RELAPSE PREVENTION (NRP) NECESSARY? (1992) (0)
Statement on the debate about second-generation antipsychotics (2010) (0)
Des-Tyr1-gamma-endorphin in schizophrenia. (1980) (0)
Subjective quality of life and treatment strategies in schizophrenia outpatient care (2004) (0)
Sesgo lingüístico en neurociencia: ¿está situada la Torre de Babel en Alemania? (2004) (0)
["More is less": a retrospective study of haloperidol dosages in acute schizophrenia]. (2000) (0)
Medication adherence studies in schizophrenia. Authors' reply (2004) (0)
Improved outcome in psychotic patients treated with risperidone long acting injectable: Experience in German patients (2004) (0)
Clinical trial of des-tyrosyl-gamma-endorphin in mental illness. (1982) (0)
P.2.076 Strategies for assuring continuity of antipsychotic treatment at the interface between inpatient and outpatient treatment of patients with schizophrenia (2003) (0)
Review: little evidence to support dose escalation of selective serotonin reuptake inhibitors in non-responders (2007) (0)
What general practitioners recommend to psychiatric patients (2000) (0)
Lithium for schizophrenia (Withdrawn Paper. 2007, art. no. CD003834) (2007) (0)
Preface (1994) (0)
„Patients consult patients“: first results (2005) (0)
Carbamazepine for schizophrenia: A systematic review and meta-analysis (2000) (0)
Dr. Hamann and Colleagues Reply (2006) (0)
PsychiatristandPatientResponsesto SuspectedMedicationNonadherence inSchizophreniaSpectrumDisorders (2014) (0)
A meta-analysis comparing “atypical” antipsychotis with low-potency conventional antipsychotics. Is less more? (2003) (0)
Authors' reply (New generation versus conventional antipsychotics) (2003) (0)
An international survey on information needs of patients with schizophrenia and their carers and management issues most frequently encountered by professional care team members (2000) (0)
Compliance in schizophrenic patients: A cross-sectional study (2005) (0)
Structure and Fluid Flow in Andesitic Systems of the Taupo Volcanic Zone: a Framework to Unravel Subseafloor Hydrothermal Flow Pathways at Brothers Volcano, Kermadec Arc? (2018) (0)
A German psychiatric care program aiming to improve patients’ compliance – Patients’ view (2022) (0)
Cost effectiveness of different treatment strategies in schizophrenia outpatient care (2004) (0)
P.6.065 Anti-stigma projects against the discrimination of psychiatric patients. A literature search and a world-wide survey (2004) (0)
P.2.147 Antipsychotic medication and treatment outcome in schizophrenia outpatient care (2004) (0)
Maintenance Treatment With Antipsychotic Drugs in Schizophrenia: A Cochrane Systematic Review and Meta-analysis. (2022) (0)
P.3.133 Risperidone long acting injectable in elderly psychotic patients: assessment of tolerability and efficacy (2005) (0)
P.2.112 Is quality management in schizophrenia outpatient care cost effective? (2004) (0)
The schizophrenic relapse is prevented by psychoeducation (2007) (0)
Is Carbamazepine Able to Increase the Antimanic Effect of Haloperidol? (1986) (0)
Modern depot treatment reckons itself Munich Compliance programme becomes a thing (2008) (0)
New generation versus conventional antipsychotics. Authors' reply (2003) (0)
SARS genome patent : to manage and to share (2005) (0)
Carbamazepine for schizophrenia and schizoaffective psychoses. (2000) (0)
P.2.127 An anti-stigma project for students: Increasingthe knowledge about schizophrenia and reducing psychiatric stigma (2004) (0)
Depot antipsychotics - an old fashioned treatment? (2004) (0)
Prospective CYP2D6 genotyping in psychiatric inpatients. A preliminary report. (2003) (0)
[Stigmatization of the mentally ill: is it our problem?]. (2000) (0)
A Meta-analysis of studies with the atypical antipsychotic amisulpride (2003) (0)
Action of [Des-Tyr1]-gamma-endorphin in schizophrenia. (1981) (0)
[Controlled study on the possible benefits of combination therapy with chlorimipramine and haloperidol inpatients with endogenous depression]. (1984) (0)
Do physicians inform themselves and their patients in a balanced manner (2008) (0)
Concluding remarks (1994) (0)
Psychotropic polypharmacy. An analysis of a large outpatient prescription database (2004) (0)
P.2.141Subjective quality of life and medication strategies in schizophrenia care (2004) (0)
TRH-Test and Psychiatric Disorders (1986) (0)
[Satisfaction with an integrated care program for outpatients with schizophrenia or depression]. (2012) (0)
Ombudsmen and patients advocate in the psychiatry - A Germany wide survey (2007) (0)
How do psychiatrists and schizophrenic patients assess treatment and outcome in outpatient care (2004) (0)
Intermediate Metabolizers And Increased Risk Of Adverse Events in Psychiatric In-patients. an Update Including All Relevant Alleles With Reduced Function and Applying Gene-dose for Analysis: 170 (2005) (0)
Results of a pilot study about the effects of a new, video based psychoeducational program for neuroleptic relapse prevention (2004) (0)
Peer-to-peer education in schizophrenia: Impact for knowledge, compliance with neuroleptic relapse prevention and quality of life (2004) (0)
Anti-stigma campaign via the Internet (2001) (0)
Cochrane reviews: their importance for psychiatry (2006) (0)
New generation versus conventional antipsychotics [3] (multiple letters) (2003) (0)
CYP2C19*2 but not*17 Influence Amitriptyline and Citalopram Serum Concentrations: Intermediate Metabolizer Status may be of Clinical Relevance (2009) (0)
META-ANALYSIS OF ANTIPSYCHOTIC DRUGS IN SCHIZOPHRENIA (2011) (0)
Integrierte Versorgung/Disease Management (2008) (0)
[Shared decision making--from a model project towards implementation]. (2004) (0)
Do schizophrenia patients want to be involved in their treatment? - Reply (2006) (0)
[Monetary incentives to improve compliance]. (2009) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With W. Daniel Kissling?

W. Daniel Kissling is affiliated with the following schools:

W. Daniel Kissling's Academic­Influence.com Rankings